FDA’s FY 2013 Drug GMP Warning Letters
This article was originally published in The Gold Sheet
Executive Summary
Topicals and injectables were the most common types of products to receive drug GMP warning letters in FY 2013. All 43 warning letters are listed here by dosage form with the key issues described.
You may also be interested in...
Vaccine Hesitancy May Drive Distribution Priorities For Early COVID-19 Supply
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.
China’s Cosmetic Animal-Testing Exemption ‘Not A Terribly Meaningful Solution’ – PCPC
The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.
Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: